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Abstract: Burkitt’s lymphoma is a highly  aggressive
endemic, sporadic, andimmunodeficiency
immunophenotypic features. It is characterized by a high proliferation rate and propensity 
for extranodal sites such as gastrointestinal tract and reproductive organs . Brief
high-intensity  chemotherapy  regimens
prophylaxis havehad remarkable success in the treatment of this disease in the sporad
with very high complete remission rate and overall survival 
lymphoma is extremely chemosensitive, biologically targeted therapies
because current treatment options are suboptimal
or with relapsed disease.
Introduction: Burkitt's lymphoma (BL) is a small 
non-cleaved  cell  lymphoma  with  a  high 
proliferation  rate  and  characteristic  molecular 
changes  involving  the  c-MYC oncogene.  It  is  a 
clinically  distinct  and  aggressive  disease,  that 
frequently  involves  extranodal  sites,  such  as  the
gastrointestinal tract and the central nervous system 
(CNS), so that it requires urgent treatment. 
In the WHO classification three clinical variants 
are  recognized:  endemic,  sporadic  and 
immunodeficiency-associated 
1. The three subtypes 
are identical according to histological pattern, and 
they all possess chromosomal rearrangements of the 
c-MYC oncogene, that  contribut
magenesis  altering  the  mechanisms  of  cell  cycle 
regulation, cellular  differentiation,  apoptosis, 
cellular adhesion, and metabolism. BL is common 
in  children,  accounting  for  40-50%  of  childhood 
; Open Journal System 
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lymphoma is a highly  aggressive mature B-cell neoplasm consisting of 
immunodeficiency-associated variants, sharing many
immunophenotypic features. It is characterized by a high proliferation rate and propensity 
xtranodal sites such as gastrointestinal tract and reproductive organs . Brief
intensity  chemotherapy  regimens including  aggressive  central  nervous  system 
had remarkable success in the treatment of this disease in the sporad
with very high complete remission rate and overall survival  in adults. Although Burkitt's 
lymphoma is extremely chemosensitive, biologically targeted therapies should be developed, 
because current treatment options are suboptimal for patients with poor prognostic features 
lymphoma (BL) is a small 
cleaved  cell  lymphoma  with  a  high 
proliferation  rate  and  characteristic  molecular 
oncogene.  It  is  a 
clinically  distinct  and  aggressive  disease,  that 
frequently  involves  extranodal  sites,  such  as  the
tract and the central nervous system 
(CNS), so that it requires urgent treatment. 
In the WHO classification three clinical variants 
are  recognized:  endemic,  sporadic  and 
. The three subtypes 
are identical according to histological pattern, and 
they all possess chromosomal rearrangements of the 
that  contributes  to lympho-
magenesis  altering  the  mechanisms  of  cell  cycle 
cellular  differentiation,  apoptosis, 
metabolism. BL is common 
50%  of  childhood 
non-Hodgkin's lymphomas (NHL) in non
areas 
2,3. 
These data have been recently update by a study 
about  sporadic childhood BL  incidence  in  United 
States during 1992-2005, reporting over this period 
296  cases  of  children  0–14  years
for  approximately  30%  of  childhood  NHL  .  The 
distribution of the cases indicated an early age onset 
(3–5 years) and a predominance in boys (79%) and 
in non-Hispanic Whites (81%), suggesting that male 
sex  and  factors  correlated  with  race  may  be  risk 
factors for sporadic BL 
4.
These results were confirmed in another analysis 
conducted by the same Authors about age
incidence pattern for BL in US over the years 1973
2005.  In this study a novel tri/bimodal incidence 
patterns for BL emerged, which showed 
by gender but not race. In fact a notable finding was 
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cell neoplasm consisting of 
associated variants, sharing manymorphologic and 
immunophenotypic features. It is characterized by a high proliferation rate and propensity 
xtranodal sites such as gastrointestinal tract and reproductive organs . Brief-duration, 
including  aggressive  central  nervous  system 
had remarkable success in the treatment of this disease in the sporadic form, 
in adults. Although Burkitt's 
should be developed, 
h poor prognostic features 
Hodgkin's lymphomas (NHL) in non-endemic 
These data have been recently update by a study 
about  sporadic childhood BL  incidence  in  United 
2005, reporting over this period 
14  years-old,  accounting 
r  approximately  30%  of  childhood  NHL  .  The 
distribution of the cases indicated an early age onset 
5 years) and a predominance in boys (79%) and 
Hispanic Whites (81%), suggesting that male 
sex  and  factors  correlated  with  race  may  be  risk 
These results were confirmed in another analysis 
conducted by the same Authors about age-specific 
incidence pattern for BL in US over the years 1973-
2005.  In this study a novel tri/bimodal incidence 
patterns for BL emerged, which showed disparities 
by gender but not race. In fact a notable finding was Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
distinct trimodal age-specific BL incidence patterns 
among males, with three separate incidence peaks 
near ages 10, 40, and 75 years, respectively. Among 
females, the pediatric and the geriatric peaks were 
remarkable,  but  not  the  adult  one.  BL  incidence 
rates  were  significantly  higher  among  males  for 
pediatric and adult BL, but  marginally for geriatric 
patients
5.
BL also occurs in adults, with the sporadic form 
accounting  for  1–2%    of  all  adult  NHL  in  the 
western Europe and in the United States
6.
Clinical Aspects: Unique clinical features have 
been  described  among  the  3  different  variants  of 
BL, although there is considerable overlap among 
them. 
The  sporadic  form  is  mostly  characterized  by
abdominal tumours, with no specific geographic or 
climatic  distribution 
6.  It  tends  to  arise  in  the 
lymphoid  tissues  of  the  gut  and  the  upper 
respiratory tract, often presenting as masses in the 
Waldeyer ring or the terminal ileum, or even with 
massive  abdominal  involvement.  It  could  be 
associated  with  EBV  in  approximately  30%  of 
cases.
Symptoms of sporadic BL are usually aspecific: 
abdominal  pain,  nausea,  vomiting,  bowel 
obstruction,  gastrointestinal  bleeding  have  been 
reported.  Bowel  or  mesenteric  lymphonodes  are 
frequent  intra-abdominal  localizations,  but  also 
kidney,  pancreas,  liver,  spleen,  breast,  or  ovarian 
involvements can occur. At diagnosis, patients may 
have  bulky  disease  and  elevated  levels  of  lactate 
dehydrogenase and uric acid. Involvement of bone 
marrow  and  central  nervous  system  (CNS)  is 
reported  in  30-38%  and  13-17%  of  adults, 
respectively 
7-9. Bone marrow involvement is more 
comm seen in progressive disease. Iin fact Burkitt's 
leukemia is essentially considered a presentation of 
advanced stage of BL, and it includes patients with 
acute  lymphoblastic  leukemia  (1–2%),  and 
circulating  blasts  that  morphologically  and 
histologically resemble BL’s cells.
Treatment:  Before  the  advent  of  high  intensity 
chemotherapy,  BL  was  associated  with  poor 
outcomes, probably because of its high proliferative 
rate.  The  introduction  of  high  intensity  regimens 
has  significantly  changed  the  prognosis  of  this 
disease.  At present BL appears to be curable in a 
high  proportion  of  cases,  when  treated  with 
aggressive  multiagent- based  chemotherapy 
regimens. 
Evolution  of  treatment  :  The  optimal    for  BL 
evolved  over  the  last  years,  with  the  growing 
knowledge of  the  biological characteristics  of the 
disease, usc as the rapid double time of the tumor, 
the  propensity  for  extranodal  sites,  the  high 
chemosensitivity,  and  the  potential  for  CNS 
relapses.
Characteristic of BL is the chemo-sensitivity to 
single agents
1–3,6. In fact, using cyclophosphamide 
(CTX) alone, complete response (CR) rates of more 
than 70% 
3 were obtained; however the high rates of 
relapse after such treatment have induced to employ 
treatment  with  cyclical  CTX,  followed  by  two 
cycles  of  combination  therapy  with  vincristine 
(VCR),  methotrexate  (MTX)  and/or  cytosine 
arabinoside  (Ara-C)  in  the  event  of  relapsed 
disease.  Despite  the  good  results  in  patients  with 
limited disease (up to 90% survival at 100 weeks), 
most  of  patients  with  CNS  or  bone  marrow 
involvement relapsed and died 
3,6.  
Chemotherapy  approaches  in  adults  (Table  1) 
have been largely adapted from pediatric regimens 
7-9. The main regimens for the front-line therapy of 
BL are reported in Table 2. 
In 1995 and 1996, two reports documented the
success of adapting the pediatric French LMB and 
the GermanBFM regimens to the treatment of adult 
BL 
9,11.  In  a  retrospective review  65  adults  were 
treated according to the pediatric LMB 81, 84, 86, 
and  89  regimens,  consisting  of  an  initial 
cytoreductive phase, using CTX and prednisone to 
reduce the tumour burden and to minimize the risk 
of tumor lysis, followed by 2 induction cycles, 1 to 
2  consolidation  cycles,  and  1  to  4 maintenance 
cycles. In these series 58 patients (89%) achieved a 
CR with a 3-year OS of 74%, even if most patients 
hadadvanced-stage disease or evidence of leukemic 
involvement; 7 of 12 patients who presented with 
CNS involvement remained disease free up to  56 
months after therapy 
9. A prospective study of the 
LMB protocol in adults confirmed the retrospective 
findings, with a CR rate of 83% and a 2-year OS of 
66% 
12.
After the  success  in  pediatric  BL  with  the 
BFM protocols, the German Multicenter Study 
Group  for  the  treatment  of  adult ALL 
(GMALL)  developed  2  protocols,  B-NHL  83 
and  B-NHL  86,  for the  treatment  of  adult 
Burkitt’s  leukemia 
11.  Similarly  to  the  LMB
trials,  these  studies  included  a  cytoreductive 
pre-phase to minimize the risk of tumour lysis, 
after  which  6  cycles  of  alternating  chemotherapy 
regimens were given, withfractionated CTX, MTX, 
and low-dose Ara-Cin each of these alternating Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
Table 1. Results of treatment of adult sporadic BL.
CR: complete remission; DFS: disease free survival; EFS: even- free survival; OS: overall survival
cycles. In the B-NHL 86 regimen  the dose of MTX 
was escalated to 1500 mg/m
2 and ifosfamide was 
added
    to  the  B-NHL  83  regimen.  Results  were 
comparableto those noted in the French LMB trials, 
with 4- to 8-year OSreaching 49-51% 
11.
McMaster  et  al treated  20  patients with  2 
intensive inpatient induction coursesof high-dose
CTX, MTX (200 mg/m
2), bleomycin, VCR, and 
doxorubicin achieving CR in 85% of patients, with 
5-year DFS of 60% 
8. The Stanford group obtained 
similar results with a regimen containing high-dose
CTX (1500 mg/m
2) and mid-cycle high-dose MTX 
(3000 mg/m
2) administered over 6 to 9 cycles. With
this regimen, 2-year OS reached 66.8%; however, 
the  best  responses were  noted  in  patients  with 
limited-stage  disease  (a  single extra-abdominal 
tumour  site  or  a  completely  resected  intra-
abdominal disease),  where  2-year  OS  was  100%, 
compared with 53.8% in theadvanced setting 
13.
The  experiences  with  dose-dense  regimens 
culminated in the scheme reported by Magrath and 
colleagues 
10.  Pediatric  and  young  adult  patients 
with  not-cleaved  small  lymphocitic  lymphomas, 
when  high risk, were treated alternating  cycles 
with  Cyclophosfamide (CTX), Vincristine (VCR), 
doxorubicin,  high-dose  Methotrexate  (MTX )i.v.    
and intrathecal  (CODOX-M) and  cicles  including 
ifosfamide,  etoposide,  high-dose  Ara-C i.v.  and 
intrathecal (IVAC regimen),  and when   low risk 
received  three  cycles  of  CTX,  VCR,  doxorubicin 
and  high-dose  MTX (CODOX-M)
10.  This  study 
demonstrated that short courses of intensive therapy 
had excellent response rates, with 92% 2-year EFS 
both  for  children  and  adults  . Unfortunately,  the 
toxicities  reported  from  many  of  these  intensive 
regimens  are  significant,  including  neurotoxicities 
from intrathecal therapy, hematological toxicity and 
severe  mucositis.). A subsequent  international 
validation of this first impressing data, obteined in 
REFERENCE Protocol No. of
patients
Median age,
y (range) CR, % DFS, % EFS, % OS,
%
Bernstein et al 
11 Stanford 18 25 (15-75) 78 71.3
at 1 y N/A 66.8 at 2 y
Lopez et al 6
MD Anderson 
81-01 and 84-30 44 32 (17-72) 80 60 at 5 y N/A 52 at 5 y
McMaster et al
29 Vanderbilt 20 44.5 (21-69) 85 65 at 5 y N/A N/A
Divinè et al
28 ACVBP 52 34 85 N/A 47 at  5 y 53 at 5 y
Soussain et al
7 LMB 81, 84, 86 and 
89 65 26 (17-65) 89 N/A 71 at 3 y 74 at 3 y
Hoeltzer et al
9 BNHL83 24 33 (15-38) 63 50 at 8 y N/A 49 at 8 y
Hoeltzer et al
9 BNHL86 35 36 (18-65) 74 71 at 4 y N/A 51 at 4 y
LaCasce et al
12 CODOX-M/IVAC 14 47 86 72 at 21 mo N/A N/A
Mead et al
5 CODOX-M/IVAC 52 35 (15-60) 75 N/A 64.6 at 2 y 72.8 at 2 y
Thomas et al
17 Hyper-CVAD 26 58 (17-79) 81 61 at 3 y N/A 49 at 3 y
Lee et al
16 CALGB 9251 54 44 (18-71) 80 50 at 4 y N/A 52 at 4 yMedit J Hemat Infect Dis 2009; 1(2); Open Journal System 
children  and  young  adults,  came  from  an 
international cohort of more aged  patients 
7.  
The  current  approaches  to    Burkitt  ’s 
lymphoma: Over the past few years, more focus 
Table 2. Main front-line specific chemotherapy regimens used in the treatment of BL.
REGIMEN SCHEDULE
STANFORD  - Cyclophosphamide 1200 mg/m2 day 1
- Doxorubicin 40 mg/m2 day 1
- Vincristine 1.4 mg/m2 (maximum 2 mg) day 1
- Prednisone 40 mg/m2 days 1-5
- Methotrexate 3000 mg/m2 (with leucovorin rescue) day 10
- IT Methotrexate 12 mg days 1 and 10
LMB 84, 86, and 89 Cytoreductive phase (COP)
- Cyclophosphamide 300 mg/m2 day 1
- Vincristine 2 mg day 1
- Prednisone 60 mg/m2/day, days 1-7
- IT Methotrexate and Hydrocortisone day 1
Induction (COPADM1)
- Cyclophosphamide 500 mg/m2/day, days 2-4
- Doxorubicin 60 mg/m2 day 2
- Vincristine 2 mg day 1
- Methotrexate 3000 – 8000 mg/m2 over 3 hrs day 1 (with leucovorin)
- Prednisone 60 mg/m2/day, days 1-7
- IT Methotrexate and Hydrocortisone days 2 and 8
Induction (COPADM2)
- Cyclophosphamide 1000 mg/m2/day, days 2-4
- Doxorubicin 60 mg/m2 day 2
- Vincristine 2 mg days 1 and 6
- Methotrexate 3000 – 8000 mg/m2 over 3 hrs day 1 (with leucovorin)
- Prednisone 60 mg/m2/day, days 1-7
- IT Methotrexate and Hydrocortisone days 2 and 8
Consolidation x 2
- Etoposide 200 mg/m2 (LMB 86 only)
- Methotrexate 3000 mg/m2 over 3 hrs day 1 (with leucovorin)
- Cytarabine 100 mg/m2/day days 1-5 (LMB 84) or 3000 mg/m2/day
- days 2-5 (LMB 86)
- IT Methotrexate and Hydrocortisone day 2, IT Cytarabine and
- Hydrocortisone day 7
Maintenance (1-4 cycles)
- Cyclophosphamide 500 mg/m2/day, days 1-2
- Doxorubicin 60 mg/m2 day 2
- Vincristine 2 mg day 1
- Methotrexate 3000 mg/m2 over 3 hrs day 1 (with leucovorin)
- Prednisone 60 mg/m2/day, days 1-5
- IT Methotrexate and Hydrocortisone day 2
BNHL-86: 
Prephase, followed by 
alternating A/B cycles for 6 
cycles
Prephase
- Cyclophosphamide 200 mg/m2/day, days 1-5
- Prednisone 60 mg/m2/day, days 1-5
Cycle A
- Ifosfamide 800 mg/m2/day, days 1-5
- VM26 100 mg/m2/day, days 4 and 5
- Vincristine 2 mg day 1
- Cytarabine 150 mg/m2 q12 hrs x 4 doses, days 4 and 5
- Methotrexate 1500mg/m2 over 24 hours day 1 (with leucovorin)
- Dexamethasone 10 mg/m2/day, days 1-5
- IT Methotrexate 15 mg, IT Cytarabine 40 mg, IT Dexamethasone 4 mg, days 1 and 5
Cycle B
- Cyclophosphamide 200 mg/m2/day, days 1-5
- Doxorubicin 25 mg/m2/day, days 4 and 5
- Vincristine 2mg IV day 1
- Methotrexate 1500 mg/m2 over 24 hours day 1 (with leucovorin)
- Dexamethasone 10 mg/m2/day, days 1-5
- IT Methotrexate 15 mg, IT Cytarabine 40 mg, IT  dexamethasone 4 mg, day 1Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
REGIMEN SCHEDULE
CODOX-M/IVAC:
Alternate CODOX-M/IVAC
cycles for 4 cycles
CODOX-M
- Cyclophosphamide 800 mg/m2 day 1 and 200 mg/m2/day, days 2-5
- Doxorubicin 40 mg/m2/day, day 1
- Vincristine 1.5 mg/m2/day, days 1 and 8 
- Methotrexate 1200 mg/m2 over 1 h and then 240 mg/m2/hr for 23 hr (with leucovorin) day 
10
- IT Cytarabine 70 mg days 1 and 3, IT Methotrexate 12 mg day 15
IVAC
- Ifosfamide 1500 mg/m2/day days 1-5 (with mesna)
- Etoposide 60 mg/m2/day, days 1-5
- Cytarabine 2000 mg/m2 every 12 hours for 4 doses, days 1 and 2
- IT Methotrexate 12 mg day 5
Hyper-CVAD: 
Alternate cycles 1 and 2 for 8 
cycles
Cycle 1
- Cyclophosphamide 300 mg/m2 q12 hours x 6 doses, days 1-3 (with mesna)
- Doxorubicin 50 mg/m2 day 4
- Vincristine 2 mg/day, days 4 and 11
- Dexamethasone 40 mg/day, days 1-4 and 11-14
- IT Methotrexate 12 mg day 2 and IT Cytarabine 100 mg day 7
Cycle 2
- Methotrexate 1000 mg/m2 day 1 (with leucovorin rescue)
- Cytarabine 3000 mg/m2 q12 hours x 4 doses, days 2 and 3
- IT Methotrexate 12 mg day 2 and IT Cytarabine 100 mg day 7
CALGB 9251: 
Prephase, followed by
alternating cycles 2-7
Prephase
- Cyclophosphamide 200 mg/m2/day, days 1-5
- Prednisone 60 mg/m2/day, days 1-5
Cycles 2, 4, and 6
- Ifosfamide 800 mg/m2/day, days 1-5
- Mesna 200 mg/m2/day, at 0, 4, and 8 hours after ifosfamide, days 1-5
- Vincristine 2 mg day 1
- Etoposide 80 mg/m2/days, days 4 and 5
- Cytarabine 150 mg/m2/day continuous infusion, days 4 and 5
- Methotrexate 150 mg/m2 over 30 min, then 1.35 g/m2 over 23.5 hrs, day 1 (with 
leucovorin rescue)
- Dexamethasone 10 mg/m2/day, days 1-5
- IT Methotrexate 15 mg, IT Cytarabine 40 mg, IT hydrocortisone 50 mg, days 1 and 5
Cycles 3, 5, and 7
- Cyclophosphamide 200 mg/m2/day, days 1-5
- Doxorubicin 25 mg/m2/day, days 4 and 5
- Vincristine 2mg IV day 1
- Methotrexate 150 mg/m2 over 30 min, then 1.35 g/m2 over 23.5 hrs, day 1 (with 
leucovorin rescue)
- Dexamethasone 10 mg/m2/day, days 1-5
- IT Methotrexate 15 mg, IT Cytarabine 40 mg, IT hydrocortisone 50 mg, days 1 and 5 *
* Cranial irradiation 24 Gy in12 fractions after cycle 3
has been placed on identifying efficacious but less 
toxic  regimens.  Several  trials  aimed  at  reducing 
MTX-associated  toxicity,  while  maintaining  the 
treatment's efficacy. Utilizing a modified Magrath’s 
regimen,  one  small  study  treated  adults  with 
reduced  doses  of  systemic  MTX  and  intrathecal 
Ara-C, and altered the fractionated schedule for the 
CTX.  This  resulted  in  a  significant decrease  in 
neurotoxicity  and  mucositis,  and  there  were  no 
treatment-associated  deaths.  Overall,  the  2-year 
EFS  was  64%,  but  100%  for  low-risk  patients 
(normal  LDH  and  focal,  smaller  volume  tumour 
burden)  and  60%  for  high-risk  patients 
14.    This 
study proved that some patients can be effectively 
treated with lower intensity regimens, with reduced 
drug  toxicity.  The  inferior  survival  of  high-risk 
patients may reflect the change in regimen, but it 
may also be explained by other factors, different in 
the two studies. For example, the median age was 
46 years in the latter study, compared with 24 years 
for  the  original  study  by  Magrath  et  al.  It  has 
became increasingly clear that age is a significant 
prognostic  factor  related  to  survival,  as  older 
patients do not tolerate the chemotherapy as well as 
the  younger,  or  do  not  have  the  same  good 
response. This fact could be explained by the innate 
differences  in  the  biology  of  the  tumours.  The 
results  of  a  FAB/LMB96  trial  for  pediatric Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
intermediate-risk  NHL  patients  revealed  that  it  is 
possible  to  reduce  treatment  for  early  responding 
patients. In this trial, the intermediate-risk patients 
(defined  as  non-resected,  stage  I/II  and  CNS 
negative advanced-stage III/IV), who have had an 
early response to therapy (> 20% response at day 
7), could be treated with reduced doses of CTX and 
doxorubicin without a significant decrement in EFS 
and in  overall survival,  comparing to  the  original 
trial. This approach should reduce the risk of future 
toxicities such as cardiac disease or infertility 
15,16. 
With  the  Hyper-CVAD  regimen,  a  modified 
Murphy  regimen  used  to  treat  adult  Burkitt 
leukemia  at  MD  Anderson,  81%  of  patients 
achieved a CR, with a 3-year OS of 49%. Notably, 
this  study  contained  a  much  older  population  of 
patients (median age, 58 years) than that reported in 
other trials, and patients 60 years or older had an 
inferior outcome (3-year OS of 17% versus 77%) 
17.                                                                                                           
The  CALGB  regimen  contains  a  cytoreductive 
phase,  followed  by  3  cycles,  each  of  2  different 
regimens administered every  3  weeks [18].  In 54 
evaluable patients, CRs were noted in 80%, with 4-
year  DFS  of  50%.  However,  severe  neurologic 
toxicity  was observed in 10 of 74 patients enrolled 
on this trial, attributed to the combination of high-
dose  MTX  (1500  mg/m2),  triple  intrathecal 
chemotherapy, and whole brain irradiation (24 Gy) 
used  for  CNS  prophylaxis.  The  cranial  radiation 
was  subsequently  eliminated  for  patients  without 
bone marrow involvement at presentation and  the 
rate of  neurologic  events
decreased.  In  the  CALGB  study,    32%  of 
patients older than 50 years were able to complete 6 
to  7  cycles  of  treatment,  compared  with  79%  of 
younger patients .Mortaliy (21% versus 9%) disease 
progression (32% versus 3% ), and toxicity (16% 
versus 9%) were noted to be higher in those patients 
older than 50 years 
8. The higher rate of relapse in 
elderly  patients  with  BL  implies  that  these  poor 
outcomes may not simply be related to treatment-
related toxicity. 
Thomas  et  al  noted  an  increased  incidence  of 
complex cytogenetic abnormalities in older patients, 
including  bcl-2  gene  rearrangements,  which  may 
contribute to  a  more aggressive phenotype 
19.    A 
prospective  study  of  dose-modified  CODOX-
M/IVAC  was  recently  conducted  in  patients  with 
sporadic  BL,  defined  using  cytogenetic  and 
immunophenotypic criteria; immunophenotype and 
fluorescent in situ hybridization (FISH) were used 
to  separate  BL  from  other  aggressive  B-cell 
lymphomas.    Compared  with  the  previous  trial 
LY06 with full-dose MTX (6.7 g/m(2) 
5, there was 
a reduction in toxicity with comparable outcomes in
patients treated dose-modified  CODOX-M (MTX, 
dose 3 g/m
2) with or without IVAC, according to 
risk group 
20.
Monoclonal antibodies and new drugs: It seems 
interesting  the  use  of  monoclonal  antibodies  and 
other biological reagents as adjuvant therapy in BL. 
These  include  agents  such  as  anti-CD20 
monoclonal antibody (Rituximab). It has been used 
most extensively with CTX, VCR, doxorubicin and 
dexamethasone  [17,21]  or  with  ifosfamide, 
carboplatin,  etoposide  in  children  with  refractory 
BL 
22.
A recent study of 31 patients treated with hyper-
fractionated  CTX,  VCR,  doxorubicin,  and 
dexamethasone  (hyper-CVAD)  regimen  plus 
rituximab  demonstrated  a  significant  increase  in 
overall survival, EFS and disease-free survival (89, 
80  and  88%,  respectively),  when  compared with 
historical  patients  treated  with  CTX,  VCR, 
doxorubicin and dexamethasone alone 
17. 
Interestingly, preliminary results of 19 patients 
(median  age  29  years,  with  53%  advanced  stage 
III/IV)  with  BL  treated  using  dose-adjusted 
etoposide, prednisone, VCR, CTX and doxorubicin 
and  rituximab  (a  known  effective  therapeutic 
regimen  for  the  treatment  of  DLBCL);  remission 
was obtained in all patients, without any relapses 
reported, with an average follow-up of 28 months. 
In  addition,  the  therapy  was  administered  in  an 
outpatient, on the basis of the minimal side effects 
reported 
21. 
Other  biological  agents  include  monoclonal 
antibodies  such  as  anti-CD22  (epratuzumab),  in 
study  for  the  treatment  of  NHL.  Respect  to 
rituximab, it has a different mechanism of action, 
but  they could  be synergistic  in  inducing cellular 
apoptosis 
23. 
Novel treatment options are developed basing on 
the rapidly growing knowledge about the molecular 
biology  of  this  disease.  In  early  development  are 
epigenetic  regulators such  as  histone deacetylases 
inhibitors  and  DNA  methyltransferases  inhibitors. 
Among  them,  Depsipeptide  is  a  histone 
deacetylases inhibitor under investigation, because 
it  has  been  shown  to  have  an  additive  cytotoxic 
effect  with  many  of  the  standard  chemotherapies 
used for the treatment of lymphomas and leukemias 
(including BL) 
24. 
Other agents can theoretically be used to target 
oncogenes, such as small peptide nucleic acids. A 
recent study showed that BL developing in severe 
combined  immunodeficient  mice  can  be  inhibited Medit J Hemat Infect Dis 2009; 1(2); Open Journal System 
by  a  peptide  nucleic  acid  complementary  to 
regulatory  intronic  sequences,  reducing  c-myc
production. Boffa and colleagues  demonstrated a 
significant reduction in tumour size and progression 
of  disease  after  the  use  of  small  peptide  nucleic 
acids complementary to a regulatory sequence for c-
myc
25,26.
Hemopoietic stem cell transplantation: The role 
of stem cell transplantation in the treatment of BL 
has been explored over the past 12 years. Several 
studies  have  focused  on  the  potential  benefit  of 
high-dose  chemotherapy  followed  by  autologous 
stem  cell  transplantation,  with  some  promising 
results in response rates and overall survival 
27,28. A 
recent  phase  II  study  for  adult  patients  by  van 
Imhoff et al 
29 utilized an up-front short intensive 
chemotherapy course followed by autologous stem 
cell  transplantation:  this  scheme  resulted  in 
equivalent,  or  slightly  better,  5-year  EFS  and 
overall  survival  compared with  current 
chemotherapy regimens. One of the limitations for 
the study was the low number of patients with bone 
marrow involvement, compared with other studies 
utilizing  intensive chemotherapy. It has been well 
documented  that  bone  marrow  involvement  is  a 
known poor prognostic indicator for BL 
30,31.
In  addition,  there  have  been  reports  of 
retrospective  evaluations  of  allogeneic 
transplantation  for  BL.  The  theoretical  benefits 
include  the  removal  of  the  possibility  of  tumour 
contamination, and the still controverse graft versus 
lymphoma effect. Such reports show lower relapse 
rates  for  patients  receiving  allogeneic 
transplantation  when  compared  with  recipients  of 
autologous  transplantation,  but  unfortunately  with 
higher rates of transplant-related mortality 
32. At the 
same  time,  there  have  been  case-reports  of 
allogeneic  transplantations  leading  to  complete 
response  and  long  survival  of  individual  patients 
33,34.  The  existence  of  a  significant  graft  versus 
lymphoma  effect  from allogeneic  stem  cell 
transplantation is still widely debated 
33,35. 
At this time the  role of hemopoietic stem cell 
transplant for BL is difficult to be defined.
Conclusions:  The  behaviour  of  BL  to 
chemotherapy  approaches  represents  a  very 
interesting point.  In the past it was thought to be an 
incurable  disease  in  adults  because  of  its  high 
proliferative  rates,  but  the  incorporation  in 
treatment  regimens  of  several  active  agents, 
particularly of the cyclophosphamide and the high-
dose methotrexate, improved the outcome in these 
patients,  reaching  a  very  high  cure  rate.  A 
maintenance    phase  does  not  seem  to  add  an 
amelioration  of  outcome,  while  the  prognosis  of 
patients has further improved after the addition of 
rituximab  to  chemotherapy  regimens.  The  use  of 
hemopoietic  stem  cell  transplantation  remains 
experimental, and it should be reserved for younger 
patients with refractory or resistant disease. 
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